The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
In the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Flagged first, then by citations
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
Items 401–500 of 1,000
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Lala, A., Coca, S. G., Feinman, J., HAMO, C. E., Fiuzat, M., Abraham, W. T., O’Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cavagna, I., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.041 · Cited by 31
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F. (2025) · Biomedicines · doi:10.3390/biomedicines13030608 · Cited by 32
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29
Savarese, G., Uijl, A., Lund, L. H., Anker, S. D., Asselbergs, F. W., FITCHETT, D. H., Inzucchi, S. E., Koudstaal, S., Ofstad, A. P., Schrage, B., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.05.012 · Cited by 29
Self-citationIlyas, F., Jones, L., Tee, S. L., Horsfall, M. J., Swan, A., Wollaston, F., Hecker, T., Pasquale, C. D., Thomas, S., Chong, W., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13553 · Cited by 29
Bayés‐Genís, A., Aimo, A., Metra, M., Anker, S. D., Seferovic, P. M., Rapezzi, C., Castiglione, V., Núñez, J. E., Emdin, M., Rosano, G. M. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2542 · Cited by 30
Self-citationBaek, J. H., Yang, Y., Ko, S., Han, K., Kim, J. H., Moon, M. K., Park, J. S., Lee, B., Oh, T. J., Chon, S., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0002 · Cited by 29
Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 29
Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality
Lezoualc’h, F., Badimón, L., Baker, H. E., Bernard, M., Czibik, G., de Boer, R. A., d’Humières, T., Kergoat, M., Kowala, M. C., Rieusset, J., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac152 · Cited by 29
Halvorsen, Y. C., Lock, J. P., Frías, J. P., Tinahones, F. J., Dahl, D. B., Conery, A. L., & Freeman, M. W. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14875 · Cited by 29
Moghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 30
Schechter, M., Wiviott, S. D., Raz, I., Goodrich, E. L., Rozenberg, A., Yanuv, I., Murphy, S. A., Zelniker, T. A., Fredriksson, M., Johansson, P. A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00009-8 · Cited by 29
Self-citationEffects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
Yu, M., Vart, P., Jongs, N., Correa‐Rotter, R., Rossing, P. R., McMurray, J. J. V., Hou, F. F., Douthat, W., Khullar, D., Langkilde, A. M., et al. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08397-9 · Cited by 28
Greene, S. J., Butler, J., & Kosiborod, M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.019 · Cited by 28
Chioncel, O. D., Čelutkienė, J., Bělohlávek, J., Kamzola, G., Lainščak, M., Merkely, B. P., Miličić, D., Nessler, J., Ristić, A. D., Sawiełajc, L., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14687 · Cited by 28
Self-citationMahmood, A., Dhall, E., Primus, C., Gallagher, A. M., Zakeri, R., Mohammed, S. F., Chahal, C. A. A., Ricci, F., Aung, N., & Khanji, M. Y. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae053 · Cited by 29
Wilding, J. P. H., Evans, M., Fernando, K., Górriz, J. L., Cebrián, A., Diggle, J., Hicks, D., James, J., Newland‐Jones, P., Ali, A., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01228-w · Cited by 28
Harrington, J., Petrie, M. C., Anker, S. D., Bhatt, D. L., Jones, W. S., Udell, J. A., Hernandez, A. F., & Butler, J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2847 · Cited by 28
Self-citationSGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
Jhund, P. S. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.010 · Cited by 30
Gudenkauf, B., Shaya, G. E., Mukherjee, M., Michos, E. D., Madrazo, J., Mathews, L. M., Shah, S. J., Sharma, K., & Hays, A. G. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.06.008 · Cited by 28
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 30
Llàcer, P., Romero, G., Trullàs, J. C., de la Espriella, R., Marcos, M. C., Quiroga, B., Casado, J., Slon-Roblero, M. F., Morales‐Rull, J. L., Morgado, J. I., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.01.003 · Cited by 27
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 27
Liao, L., Zhang, L., Yang, C., Wang, T., Feng, L., Peng, C., Long, Y., Dai, G., Chang, L., Yan, W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106598 · Cited by 27
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 33
Heart failure population health considerations
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88673 · Cited by 31
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Severino, P., D’Amato, A., Prosperi, S., Costi, B., Angotti, D., Birtolo, L. I., Chimenti, C., Lavalle, C., Maestrini, V., Mancone, M., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10170-1 · Cited by 27
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Amin, N. U., Sabir, F., Amin, T., Sarfraz, Z., Sarfraz, A., Robles‐Velasco, K., & Chérrez-Ojeda, I. (2022) · Healthcare · doi:10.3390/healthcare10122356 · Cited by 27
Management of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 31
Theofilis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13020497 · Cited by 28
Swat, S. A., Xu, H., Allen, L. A., Greene, S. J., DeVore, A. D., Matsouaka, R., Goyal, P., Peterson, P. N., Hernandez, A. F., Krumholz, H. M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.04.015 · Cited by 27
Singh, L. G., Ntelis, S., Siddiqui, T., Seliger, S. L., Sorkin, J. D., & Spanakis, E. K. (2023) · Diabetes Care · doi:10.2337/dc23-1129 · Cited by 27
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 31
Kittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000132 · Cited by 28
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Jaiswal, V., Ang, S. P., Kumar, D., Deb, N., Jaiswal, A., Joshi, A., NASIR, Y. M., Bandyopadhyay, D., Michos, E. D., Benjamin, E. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101615 · Cited by 26
Koufakis, T., Mustafa, O. G., Tsimihodimos, V., Ajjan, R., & Kotsa, K. (2021) · Drugs · doi:10.1007/s40265-021-01559-1 · Cited by 26
Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
Sayour, A. A., Ruppert, M., Oláh, A., Benke, K., Barta, B. A., Zsáry, E., Merkely, B. P., & Radovits, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189852 · Cited by 28
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 26
McNaughton, C. D., McConnachie, A., Cleland, J. G. F., Spertus, J. A., Angermann, C. E., Duklas, P., Tromp, J., Lam, C. S. P., Filippatos, G. S., Dahlström, U., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2508 · Cited by 27
Reis, J., Teixeira, A. R., Gonçalves, A. V., Moreira, R. I., Pereira‐da‐Silva, T., Timóteo, A. T., & Ferreira, R. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102935 · Cited by 26
Mottl, A. K., & Nicholas, S. B. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.003 · Cited by 27
Margolin, E., Huynh, T., Brann, A. M., & Greenberg, B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100818 · Cited by 26
Tanaka, A., Kida, K., Matsue, Y., Imai, T., Suwa, S., Taguchi, I., Hisauchi, I., Teragawa, H., Yazaki, Y., Moroi, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae561 · Cited by 26
SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy
Anker, S. D., Usman, M., & Butler, J. (2022) · Circulation · doi:10.1161/circulationaha.122.060348 · Cited by 26
Seidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.303 · Cited by 25
Elian, V., Popovici, V., Karampelas, O., Pîrcălăbioru, G. G., Radulian, G., & Muşat, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041972 · Cited by 25
Kittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.014 · Cited by 27
Piperis, C., Marathonitis, A., Anastasiou, A., Theofilis, P., Mourouzis, K., Giannakodimos, A., Tryfou, E. S., Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12102314 · Cited by 26
Tailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction
Inciardi, R. M., Riccardi, M., Savarese, G., Metra, M., Vaduganathan, M., & Solomon, S. D. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3558 · Cited by 26
Self-citationLiang, I.-C., Chang, H.-H., Lai, Y.-J., Chan, C.-M., Sung, C.-H., Pu, C., Chang, D., Ho, C.-C., & Hung, C. (2025) · Medicina · doi:10.3390/medicina61020202 · Cited by 25
Schechter, M., Cohen, C. M., Rozenberg, A., Yanuv, I., Chodick, G., Karasik, A., Kosiborod, M., & Mosenzon, O. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01362-y · Cited by 25
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 25
Yanucil, C., Kentrup, D., Li, X., Grabner, A., Schramm, K. J., Martinez, E. C., Li, J., Campos, I. D., Czaya, B. A., Heitman, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11033-x · Cited by 25
Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes
Claggett, B. L., McCaw, Z. R., Tian, L., McMurray, J. J. V., Jhund, P. S., Uno, H., Pfeffer, M. A., Solomon, S. D., & Wei, L. (2022) · NEJM Evidence · doi:10.1056/evidoa2200047 · Cited by 28
Lee, C., Wu, M., Lui, D. T. W., Fong, C., Ren, Q. W., Yu, S. Y., Yuen, M., Chow, W., Huang, J., Xu, A., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01646-x · Cited by 26
Rong, X., Zhu, Y., Bo, W., Liu, K., Li, X., Gou, Q., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.973129 · Cited by 27
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Tamargo, J. L., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinándy, P., Grove, E. L., Rocca, B., Magavern, E. F., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae013 · Cited by 25
Docherty, K. F., & McMurray, J. J. V. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2075 · Cited by 25
Drazner, M. H. (2021) · New England Journal of Medicine · doi:10.1056/nejme2113008 · Cited by 25
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 24
Yoo, T. T., Baek, I. H., Stoletniy, L. N., Hilliard, A. A., Sakr, A. E., & Doycheva, D. M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02777-7 · Cited by 24
Duan, X.-Y., Liu, S.-Y., & Yin, D. (2021) · Medicine · doi:10.1097/md.0000000000026431 · Cited by 24
Ahmad, Y., Madhavan, M. V., Stone, G. W., Francis, D. P., Makkar, R., Bhatt, D. L., & Howard, J. P. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab072 · Cited by 24
Self-citationAlkabbani, W., Pelletier, R., Beazely, M. A., Labib, Y., Quan, B., & Gamble, J. (2022) · Drug Safety · doi:10.1007/s40264-022-01166-3 · Cited by 24
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
Voorrips, S. N., Saucedo‐Orozco, H., Sánchez-Aguilera, P., de Boer, R. A., van der Meer, P., & Westenbrink, B. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158631 · Cited by 24
Wang, N., Evans, J., Sawant, S., Sindone, J., & Lal, S. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10275-1 · Cited by 25
Voorrips, S. N., Boorsma, E. M., Beusekamp, J. C., de Boer, R. A., Connelly, M. A., Dullaart, R. P. F., VAN-DER-MEER, P., VANVELDHUISEN, D. J., Voors, A. A., Damman, K., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.09.009 · Cited by 24
Self-citationLau, D., Pannu, N., Yeung, R. O., Scott‐Douglas, N., & Klarenbach, S. W. (2023) · CMAJ Open · doi:10.9778/cmajo.20210281 · Cited by 24
SGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 24
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 24
Garg, R., Sood, N., Bansal, O., & Hoskote, A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09073-2 · Cited by 23
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25
Nightingale, B. (2021) · Cardiology Research · doi:10.14740/cr1221 · Cited by 23
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 23
Chun, K. J., & Jung, H. H. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.04.009 · Cited by 23
Bhatt, A. S., ADLER, E. D., Albert, N. M., Anyanwu, A., Bhadelia, N., Cooper, L. T., Correa, A. A., DeFilippis, E. M., Joyce, E., Sauer, A. J., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.08.013 · Cited by 24
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 23
Maddaloni, E., Cavallari, I., Porta, Y. L., Appetecchia, A., D’Onofrio, L., Grigioni, F., Buzzetti, R., & Holman, R. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14986 · Cited by 25
STOUGAARD, E. B., Rossing, P. R., Vistisen, D., Banks, P. L., Girard, M., Davies, M. J., & Persson, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15047 · Cited by 23
Sanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 24
Potential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Docherty, K. F., Solomon, S. D., McMurray, J. J. V., Januzzi, J. L., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2864 · Cited by 23
State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs
Vincenti, F. G., Angeletti, A., & Ghiggeri, G. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167741 · Cited by 24
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Connelly, K. A., O’Meara, E., Zieroth, S. R., & Sherifali, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02154-w · Cited by 23
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
Li, X., Zhang, Q., Zhu, L., Wang, G., Ge, P., Hu, A., & Sun, X. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.03.077 · Cited by 23
Fauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
Qiu, M., Ding, L., & Zhou, H. (2021) · Medicine · doi:10.1097/md.0000000000025121 · Cited by 22
Timely and individualized heart failure management: need for implementation into the new guidelines
Abdin, A., Bauersachs, J. K., Frey, N., Kindermann, I., Link, A., Marx, N., Lainščak, M., Slawik, J., Werner, C. M., Wintrich, J., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01867-2 · Cited by 22
Shrestha, D. B., Budhathoki, P., Sedhai, Y. R., Karki, P., Gurung, S., Raut, S., Damonte, J. I., Buono, M. G. D., Mojadidi, M. K., Elgendy, I. Y., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001099 · Cited by 23
EMPEROR-Preserved: A promise fulfilled
Bhatt, D. L., Verma, S., & Pitt, B. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.10.011 · Cited by 22
Self-citationPerez-Belmonte, L. M., Sanz‐Cánovas, J., Millán‐Gómez, M., Osuna‐Sánchez, J., Sampalo, A. L., Ricci, M., Jiménez-Navarro, M. F., Lopez-Carmona, M. D., Bernal-López, M. R., Barbancho, M. Á., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17585 · Cited by 22
Yin, Z., Zheng, H., & Guo, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.902923 · Cited by 22
Maryniak, A., Maisuradze, N., Ahmed, R., Biskupski, P., Joseph, J., & Budzikowski, A. S. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0051 · Cited by 22
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Kansara, A., Mubeen, F., & Shakil, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1120 · Cited by 22
Medication-Attributable Adverse Events in Heart Failure Trials
Harrington, J., Fonarow, G. C., Khan, M. S., Hernandez, A. F., Anker, S. D., Böhm, M., Greene, S. J., Felker, G. M., Vaduganathan, M., & Butler, J. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.026 · Cited by 22
Chatur, S., Cunningham, J. W., Vaduganathan, M., Causland, F. R. M., Claggett, B. L., Desai, A. S., Miao, Z. M., Jhund, P. S., de Boer, R. A., Hernandez, A. F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2915 · Cited by 22
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 22
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
